Observational studyJournal of comparative effectiveness research2025

Longer disease progression milestone-free time in people with amyotrophic lateral sclerosis treated versus not treated with intravenous edaravone: results from an administrative claims analysis.

James D Berry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.